News
The movies introducing wheat cell-free protein synthesis technology and its applications is now available on the Protein Island Matsuyama (PIM) website.
The movies introducing the wheat cell-free protein synthesis technology and its applications was created and released as one of the programs of Protein Island Matsuyama (PIM) 2020,
CellFree Sciences Co., Ltd. received support from Ehime Prefecture under the "Ehime Prefecture New Growth Manufacturing Company Comprehensive Support Program in FY2021".
We are grateful, that Ehime Prefecture selected an application by CellFree Sciences under their "Ehime Prefecture New Growth Manufacturing Company Comprehensive Support Program in FY2021".
Having access to a unique set of about 23,000 human full-length proteins, CellFree Sciences will apply their own technologies including a protein bead array platform to search for new drug targets and therapeutic concepts.
While about 10 to 15% of the human proteins could play a role in disease, presently only about 2% of the human proteins can be directly targeted by a drug. Hence, there is a clear need to expand the number of druggable proteins to develop new therapeutic concepts and to cover a wider range of disease. In this project, we will apply new concepts to target drug targets for proteolytic degradation utilizing E3 ligases. Having extensive knowledge on E3 ligases, it is hoped that utilizing E3 ligases will offer new leads allowing for targeted proteolysis of selected targets while having less side effects than other drug candidates.
Project period: July 5, 2021-February 28, 2022.
We will be at BIO Digital 2021
CellFree Sciences will be at Bio Digital 2021 from June 10 to 18, 2021.
Please visit us from Partnering system
We are looking forward to welcome you and to provide you with more information on the use of our protein expression products and services.
Dr. Yaeta Endo, Special University Professor Emeritus, received the Ehime News Paper's Award
Dr. Yaeta Endo, who is the Special University Professor Emeritus, received the Ehime News Paper’s Award for developing wheat germ cell free protein expression system.
Changing procedures for kit manuals from May 10, 2021
Thank you very much indeed for working together with CellFree Sciences and using our cell-free protein expression system in your work.
CellFree Sciences wants to contribute to the global efforts to reduce paper usage. Therefore, we have decided to ship from May 10, 2021, all our reagents and kits without a printed manual.
All our manuals are available for download on our homepage and directions on how to access the manuals and other product related information will be attached to each shipment for guiding our customers.
If you have any questions on the use of our products or how to access the product manuals, please contact us.
We are happy to assist you and to send you a PDF version of our manuals.
Thank you for your understanding and support! We hope our customers will appreciate our efforts to reduce paper use by switching to paperless notes or keeping the number of printed pages to a minimum.
The GHIT Fund of Japan continues their support for the development of a malaria transmission-blocking vaccine.
The GHIT Fund of Japan announced on March 31, 2021, their new investments to support global R&D projects for neglected tropical diseases. This includes new funding for a First-In-Human Trial of the Pan-Malaria Transmission-Blocking Vaccine AnAPN1.
CellFree Sciences is most grateful for the continuous support given by the GHIT Fund for the development of an AnAPN1-based malaria transmission-blocking vaccine! In a project led by Prof. Rhoel Dinglasan at the University of Florida, we had been working together for several years on the development of an optimized antigen focusing on the transmission-blocking domain in the AnAPN1 protein. With the new GHIT funding, we will now move this new antigen to clinical development in Gabon.
We are looking forward to working together with Ajinomoto Bio-Pharma Services, GeneDesign, the Centre de Recherches Médicales de Lambaréné (CERMEL), University of Tübingen and The University of Florida to make this important project successful. It is our hope that this vaccine will in the future contribute to better malaria control and eradication.
Project description on GHIT Webpage:
CellFree Sciences responded to new State of Emergency in Japan
On February 2nd, 2021, the Government of Japan extended the Coronavirus State of Emergency for Tokyo, Osaka and eight other prefectures for one more month. The new measures will be in effect until March 7th, 2021 according to the present government plans.
CellFree Sciences is fully supporting the actions of the Japanese Government! We have therefore extended also our own actions to protect our staff following government directions and to make our contribution to help stopping the further spread of the virus.
We will keep on making best efforts to support our customers also during the State of Emergency.
All orders will be processed as usual as we know about the importance of the work our customers are doing.
Please contact us for more information.
Outlook for 2021 from CellFree Sciences
Our outlook for 2021 written by Ozawa, the President and CEO of CellFree Sciences Co., Ltd., was published on the international industry journal MED TECH Outlook.
A set of 1118 human transcription factors was made by our expression system to study side effects of "thalidmide"
A joint effort by several universities and research institutes in Japan, including our strategic technology partners Dr. Satoshi Yamanaka and Professor Tatsuya Sawasaki at the Proteoscience Center of Ehime University, conducted a comprehensive study using a human protein array comprising 1,118 human transcription factors produced in our wheat germ cell-free protein expression system. Screening those proteins led to the discovery that thalidomide and its metabolite 5‐hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF.
Thalidmide was originally used as a sleeping drug for pregnant women but had caused terrible side effects. Later it was found that Thalidmide and its derivatives are potent drugs for treating leprosy and multiple myeloma. These are highly effective drugs that are now sold for about 1 trillion yen per year in the world for treatment of blood cancers such as multiple myeloma. However, these drugs require a strict safety management to avoid teratomas. The new finding reported here will help to develop better thalidmide derivatives that could avoid any risk for teratoma formation.
For details, please click here.
Please click here for a paper on this research.
CellFree Sciences responded to new State of Emergency in Japan
On January 7th, 2021, the Government of Japan declared the State of Emergency for Tokyo and the three neighboring prefectures of Kanagawa, Saitama and Chiba in response to claiming numbers of COVID-19 cases in the area. The new measures will be in effect until February 7th, 2021 according to the present government plans.
CellFree Sciences is fully supporting the actions of the Japanese Government! We have taken actions to protect our staff following government directions and to make our contribution to help stopping the further spread of the virus.
We will make best efforts to support our customers also during the State of Emergency.
All orders will be processed as usual as we know about the importance of the work our customers are doing.
Please contact us for more information.
